We work with all biopharmaceutical companies regardless of size and therapeutic area.

Rapid Quality Evaluation (RQE) involves a rapid, high level health care quality evaluation on the specific therapeutic area designated by biopharmaceutical clients that provides insight on provider and payer customer pain points and opportunities to inform a specific area of internal business strategy.

Patient-centeredness and health equity are cross-cutting themes that are reflected in RQE and all other THCQ Consulting services.

Comprehensive Quality Evaluation (CQE) involves an extensive and comprehensive quality evaluation and assessment on a specific therapeutic area of focus designated by biopharmaceutical clients.  CQE involves advising on health care quality and the external value-based care environment to inform internal business strategy in the areas of evidence generation, external stakeholder engagement, market development, market access, and payer marketing.

Patient-centeredness and health equity are cross-cutting themes that are reflected in CQE and all other THCQ Consulting services. 

Expert Quality Advisory Retainer (EQAR) services involve retained quality strategy advisory consulting where the biopharma client is availed of advisory services of THCQ Consulting President & CEO, Norris Turner, and others on the team.

The THCQ Consulting team brings strong expertise and decades of experience in the areas of health care quality strategy in life sciences, external medical and payer stakeholder engagement in support of life science company strategy, quality measure development, phase II-IV clinical development, market access, and health policy.

For THCQ Consulting overall services, we work in all therapeutic areas.  Importantly, we have particularly strong depth of knowledge, experience, and relationships in neuroscience. Patient-centeredness and health equity are cross-cutting themes that are reflected in EQAR and all other THCQ Consulting services.